SecProbe.io

CORRESP
1
filename1.htm

Clover
Leaf Capital Corp.

1450
Brickell Avenue, Suite 1420

Miami,
FL 33131

VIA
EDGAR

July
9, 2024

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

Office
of Trade & Services

Washington,
D.C. 20549

    Attention:
    Ta Tanisha Meadows

    Angela Lumley

    Brian Fetterolf

    Mara Ransom

    Re:
    Clover Leaf Capital Corp.

    Amendment No. 7 to Registration Statement on Form
    S-4

    Filed June 26, 2024

    File No. 333-274851

Ladies
and Gentlemen:

Clover
Leaf Capital Corp. (the “Company”) hereby transmits its response to the comment letter received from the staff (the
“Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) on July 1, 2024 relating
to the Amendment No. 7 to Registration Statement on Form S-4, submitted by the Company to the Commission on June 26, 2024 (the “Registration
Statement”).

For
the Staff’s convenience, we have repeated below the Staff’s comments in bold and have followed each comment with the Company’s
response. Disclosure changes made in response to the Staff’s comments have been made in Amendment No. 8 to the Registration Statement,
which is being submitted to the Commission contemporaneously with the submission of this letter.

Summary
of the Proxy Statement/Prospectus

Clover
Leaf Nasdaq Listing, page 13

1. We
                                            note your preliminary proxy statement filed June 25, 2024, which seeks to extend the date
                                            that you must consummate your initial business combination from July 22, 2024 to October
                                            22, 2024. We further note that you amended the business combination agreement so as to change
                                            the outside date from July 22, 2024 to August 30, 2024. Here or in another place in your
                                            prospectus summary, as appropriate, please revise to explain that the proposed termination
                                            deadline of October 22, 2024 and the amended outside date of August 30, 2024 contemplate
                                            a timeline for your business combination that do not comply with Nasdaq IM-5101-2, or advise,
                                            and disclose the risks of your non-compliance with this rule, including that your securities
                                            may be subject to suspension and delisting from Nasdaq, similar to the risk factor entitled
                                            “The Charter Extension contemplated by the Extension Amendment Proposal contravenes
                                            Nasdaq rules . . . ,” which we note you include on page 14 of your preliminary proxy
                                            statement.

Response:
The Company respectfully acknowledges the Staff’s comment and advises the Staff that it has amended its disclosure on pages 14–15
and 38 of the Registration Statement to include the requested information.

Item
21. Exhibits and Financial Statements Schedules., page II-2

2. To
                                            the extent that the resale prospectus contemplates offering 30% (as opposed to 20%) of the
                                            Merger Consideration as part of the Digital Ally Distribution, please revise to update Exhibit
                                            5.1 and 107. In this regard, both the legal opinion and filing fee table continue to indicate
                                            that you contemplate an offering of 20% of the Merger Consideration.

Response:
The Company respectfully acknowledges the Staff’s comment and advises the Staff that it has updated Exhibit 5.1 and 107 accordingly.

General

3. With
                                            respect to the Digital Ally Distribution, revise to select the percentage and quantify the
                                            number of shares you are registering in the distribution on page 210 consistent with Item
                                            501(b)(2) of Regulation S-K, which requires you to state the amount of securities offered
                                            at this time.

Response:
The Company respectfully acknowledges the Staff’s comment and advises the Staff that it has amended its disclosure on the cover
page and pages v, x, xxi, 2, 57, 95, 100, 187, 212, and 216 of the Registration Statement to include the requested information.

4. We
                                            note your revised disclosure that “Digital Ally intends to effect the Digital Ally Distribution
                                            by making a pro rata in-kind distribution of the securities to its stockholders and certain
                                            warrantholders pursuant to the registration statement…” Please elaborate upon
                                            the identity of the “certain” warrantholders, including the terms of such warrants,
                                            number of warrantholders and amount of warrants that will be part of the distribution and
                                            why only “certain” of your outstanding warrants will be participating in the distribution.
                                            Provide us with your analysis as to how the distribution continues to be a “pro rata
                                            in kind,” when it no longer appears that you are providing equal value because you have
                                            introduced a new class of securities.

Response:
The Company respectfully acknowledges the Staff’s comment and advises the Staff that it has revised the disclosure on the cover
page and pages iv, xix, 11, 37 and 216 of the Registration Statement.

*
* *

    2

We
thank the Staff for its review of this response. Should you have any questions or require any additional information, please do not hesitate
to contact our legal counsel, Jessica Yuan, Esq. of Ellenoff Grossman & Schole LLP, at jyuan@egsllp.com or by telephone at (212)
370-1300.

    Very truly
    yours,

    Clover Leaf
    Capital Corp.

    By:
    /s/
    Felipe MacLean

    Name:
    Felipe MacLean

    Title:
    Chief Executive Officer

    cc:
    Ellenoff Grossman &
    Schole LLP

3